SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " alzheimer " 298 found 🔀 AI-powered Shuffle
PET imaging links psychosis to Alzheimer's-related brain findings
New imaging research suggests that many adults who develop psychosis-related hallucinations or delusions later in life show brain changes associated with AD and other neurodegenerative disorders.
My mom has Alzheimer's. Caregiving never really stops.
I thought arranging 24-hour care for my mom with Alzheimer's would ease the burden. Instead, I discovered how much caregiving remained.
Thousands of people in China have had banned Alzheimer's surgery
Surgery that aims to enhance the clearance of Alzheimer's-associated proteins from the brain has been banned in China, but only after thousands of people had the procedure
Scientists discover why poor sleep may harm some brains more
A gene involved in the brain’s overnight cleaning system may change how strongly poor sleep affects Alzheimer’s-related brain changes. The findings point toward more personalized prevention strategies based on both genetics and sleep habits.
Chicago advocates step up for brain health and a future without Alzheimer’s
Content oversight provided by Studio 1847 Alzheimer’s disease reshapes families and demands immense resilience. Yet a growing wave of scientific optimism is changing approaches to brain health. Local volunteers Ellen Gudjonis and …
RFK Jr urges Alzheimer’s screening but blunts key panel that could drive research
Experts say evidence for cognitive screening desired by health secretary ‘not great’ as taskforce idle since last year
A hidden Alzheimer’s tipping point may decide who gets dementia
Scientists have identified a possible tipping point that helps determine whether Alzheimer’s-related brain changes lead to dementia. The key may lie in how the brain’s immune cells respond to plaques and tau, offering a promising new target for treatments designed to extend cognitive resilience.
Superagers keep youthful memories but their DNA does not explain why
Scientists expected SuperAgers might simply inherit fewer Alzheimer’s-related risks, but their genes looked much like those of typical older adults. Their extraordinary memories may instead come from still-unknown protective forces involving the brain, body, lifestyle, and environment.
Why Did This Man Avoid Alzheimer’s? Scientists Reveal Their Astonishing Theory - Futura-Sciences
A Family Plagued by Early-Onset Alzheimer’s Doug Whitney inherited a rare genetic mutation that’s devastated much of his family: many relatives experienced significant cognitive decline as early as their 50s. Yet Doug himself has stayed mentally alert well past the age at which illness struck in the family. According to...
Lab-grown mini brains may predict which Alzheimer’s treatments will work
Miniature brain models grown from patients’ cells revealed striking differences in how Alzheimer’s-related tissue responds to an antidepressant. The organoids and the particles they release could eventually guide more personalized treatments and provide new clues for diagnosing the disease.
Beyond weight loss: Lilly aims for leadership in brain science
Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.
Scientists discover a protein that protects the brain from Alzheimer’s damage
A protein called SORLA may act as a powerful defense against the toxic tau tangles involved in Alzheimer’s disease. Mice with extra SORLA had less tau accumulation, less brain atrophy, and healthier connections between neurons, while mice without it experienced more severe damage. The findings also revealed a possible drug target that could help control harmful activity in supporting brain cells.
5 Lifestyle Changes I Made After Learning I Have a High Alzheimer’s Risk
A mom of three, Elena Castellanos recently learned just how much power over her health she really has.
New Alzheimer's drug repairs DNA damage and reduces brain inflammation
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.
UT Health San Antonio study links sleeping long hours with higher levels of an Alzheimer’s-related protein
UT Health San Antonio study links sleeping long hours with higher levels of an Alzheimer’s-related protein
UT Health San Antonio study links sleeping long hours with higher levels of an Alzheimer’s-related protein
Findings could signal early neurodegenerative processes at work Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu SAN ANTONIO, July 16, 2026 – Regularly sleeping long hours each night is associated with higher levels of an Alzheimer’s-related protein in the blood, even accounting for other health factors, suggests a new study from UT Health San Antonio, the academic […]
In Good Health: The Alzheimer’s Research Revolution
An Alzheimer’s diagnosis can have a real impact on a person and their family. There’s a lot to consider — what the future will hold, what symptoms they’ll experience, and on what timeline.About 7.5 million people in the U.S. currently suffer from Alzheimer’s. Every year, around half a million more are diagnosed with the disease or another form of dementia. As the population gets older, that figure will continue to rise.For decades, researchers have struggled to understand these kinds of diseases. But when it comes to testing and treatment, particularly for Alzheimer’s, there have been significant advances in the past few years.In this installment of our series, “In Good Health,” we tackle the revolution in dementia research. What will that mean for patients?For more information on dementia research, find Pam Belluck’s latest reporting at the New York Times. And Dr. Karlawish’s “Neurotransmissions” column at STAT News, covering dementia care and research.Find more of our programs online. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.
In Good Health: The Alzheimer's research revolution
About 7.5 million people in the U.S. currently suffer from Alzheimer’s.
Study shows a blood test can help identify healthy people at high risk for Alzheimer's disease
A blood test that helps diagnose Alzheimer’s might also forecast if healthy older adults will develop symptoms
Study shows a blood test can help identify healthy people at high risk for Alzheimer’s disease
A blood test that helps diagnose Alzheimer's might also forecast if healthy older adults will develop symptoms.
Boundary Spanning Leadership's Impact on Public Health
Explore three examples of Boundary Spanning Leadership's public health impact, from overdose to Alzheimer's to youth behavioral health.
2 brain-healthy habits a neurologist swears by to prevent disease
A neurologist shared why emotional health is so important for reducing the risk of dementia and Alzheimer's.
Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026
New findings demonstrate the potential of OBD's MRI-based Cortical Disarray Measurement (CDM®) technology to support patient identification, disease characterization, treatment monitoring, and therapeutic development across Alzheimer's disease OXFORD, United Kingdom, July 13, 2026 (GLOBE NEWSWIRE) -- Oxford Brain Diagnostics (OBD), a leader in MRI-based measurement of brain health and neurodegenerative disease, today announced the presentation of five new studies at the Alzheimer's Association I
Alzheimer's tau protein has a surprising secret role in memory
Researchers found that tau is essential for turning new experiences into lasting memories by helping organize the brain's memory-storing cells. The mouse study also revealed how abnormal tau may contribute to Alzheimer's by disrupting both the formation of new memories and the recall of existing ones.
Science & Medicine: Pursuing precision medicine for Alzheimer's disease
A cutting-edge technology and an exciting recent hire hint at exciting developments in the future of precision medicine in the diagnosis and treatment of Alzheimer's disease.
Do You Know Your Dementia Risk?
The risk for Alzheimer's doubles every ten years after the age of 60. Knowing your risk can potentially help you prevent dementia as you age.
An anti-inflammatory diet may lower dementia risk, even in people with early signs of Alzheimer’s
Healthy eating may help protect the brain, even after early biological changes linked to Alzheimer’s disease have begun, a study suggests. Dr. Leana Wen explains.
RFK Jr.’s latest overhaul aims to boost preventive care. It could get expensive.
The health secretary wants insurers to cover Alzheimer’s tests. Some in the health industry hope he’ll back routine testing for many more diseases.
Scientists may have finally found how Alzheimer's kills brain cells
Researchers have identified a previously overlooked mechanism of brain cell death that appears to play a major role in Alzheimer's disease and frontotemporal dementia. The finding could lead to new treatments aimed at slowing neuron loss by interrupting the process before cells are destroyed.
Scientists discover the deep sleep circuit that builds muscle, burns fat, and boosts the brain
Researchers have identified the brain circuitry that links deep sleep with the release of growth hormone, revealing how the two regulate each other. The newly discovered feedback loop helps explain why poor sleep can interfere with growth, muscle repair, fat metabolism, and brain function. Understanding this system could pave the way for new therapies for sleep disorders and diseases tied to metabolism and the brain, including Alzheimer's and Parkinson's.
Could We Have Been Wrong About Fish Oil and Brain Health? New Study Raises Major Questions
Fish oil supplements delivered omega-3s to the brain, but a new study found that was not enough to improve cognitive health in older adults at risk for Alzheimer’s.
Could your gut bacteria really slow Alzheimer’s? Scientists reveal a surprising link - Futura-Sciences
European researchers previously demonstrated that transferring stool samples from human Alzheimer’s patients into healthy rats triggered symptoms like spatial memory issues. Other models show that altering gut microbes changes the buildup of amyloid plaques and tau proteins, the two main hallmarks of the disease. Scientists have even found that certain...
Danny Glover Reveals Alzheimer’s Diagnosis on TODAY: EXCLUSIVE
The 79-year-old “Lethal Weapon” star shared with Lester Holt that he was diagnosed with the progressive neurodegenerative disease a few years ago.
If you’re at risk of Alzheimer’s, these dietary habits can help, study finds
Research suggests diet remains a relevant factor for brain health even after blood markers of dementia are present.
Scientists may have finally found how Alzheimer's spreads through the brain
A common brain protein may be giving Alzheimer’s disease an unexpected way to spread, carrying toxic Tau proteins from damaged neurons into healthy ones. By blocking these harmful protein packages before they reach new cells, researchers believe it may one day be possible to slow the disease's relentless progression.
Fish oil supplements no match for Alzheimer's risk, new study finds
A new study from the Keck School of Medicine at USC found a revelation regarding fish oil supplements. Here's the researchers' findings.
How a Brain Messenger Protein Drives Progression of Alzheimer’s Disease
In mice, a brain protein called Arc helps spread toxic molecules from sick brain cells to healthy ones. If therapies could be designed to target the spread, they could be a powerful tool to stop disease progression.
Millions take omega-3 fish oil for brain health but a new study found no benefit
Fish oil supplements successfully delivered omega-3s to the brain, but a two-year study found no meaningful benefits for memory, cognition, or Alzheimer’s-related brain changes. The results challenge the idea that fish oil pills can help prevent Alzheimer’s and shift attention toward overall diet and lifestyle instead.
Millions take omega-3 fish oil for brain health but a new study found no benefit
Fish oil supplements successfully delivered omega-3s to the brain, but a two-year study found no meaningful benefits for memory, cognition, or Alzheimer’s-related brain changes. The results challenge the idea that fish oil pills can help prevent Alzheimer’s and shift attention toward overall diet and lifestyle instead.
Alzheimer’s research headlines 2026 brain health summit
The summit, hosted by the University of Hawaii John A. Burns School of Medicine, highlighted the latest advances in Alzheimer’s research.
Alzheimer’s research headlines 2026 brain health summit
The event featured presentations on recent Alzheimer’s advancements.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Think 8 Hours of Sleep Is the Best for Your Cognitive Health? A New Study Suggests Otherwise
Research reveals a hidden genetic link that dictates exactly how your nighttime routine impacts your brain.
Parenting may permanently improve brain health for mums and dads
Raising children appears to keep the brain young, potentially acting as a buffer against cognitive decline and Alzheimer’s
Is hearing loss an Alzheimer’s warning sign? Research shows new risk factors
The number of people living with Alzheimer’s disease is expected to double by 2060. New research is shedding light on warning signs and risk factors that could signal cognitive decline ahead.
Tubulin prevents toxic brain protein clumps linked to Alzheimer’s and Parkinson’s
Scientists at Baylor College of Medicine may have uncovered a promising new way to combat Alzheimer’s and Parkinson’s disease. Instead of trying to stop Tau and alpha-synuclein proteins from gathering into tiny droplets inside brain cells, the researchers found that tubulin—the protein that builds the cell’s internal transport network—can redirect these proteins away from forming toxic clumps and toward healthy, productive work.
I'm raising young kids while losing my dad to Alzheimer's
While raising two young children and expecting a third, I'm also helping care for my father as Alzheimer's slowly takes him away.
Can Better Sleep Lower Dementia Risk? What the Science Says
Poor sleep may raise your Alzheimer's risk by as much as 44%. Here's what researchers know about sleep, brain health, and what you can do tonight.
Scientists reprogram brain immune cells to fight Alzheimer’s
A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.
Alzheimer's Drug Discovery Foundation Begins Search for New Chief Science Officer as Co-Founder Dr. Howard Fillit Transitions to Emeritus Role
/PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced that its Co-Founder and Chief Science Officer (CSO), Dr. Howard Fillit, is...
Scientists May Have Found What Really Triggers Alzheimer’s Disease
Scientists may have uncovered a hidden trigger behind Alzheimer’s disease. Instead of plaques being the root cause, amyloid beta appears to interfere with tau, a protein that helps keep neurons functioning properly. This disruption could set off the damage that eventually leads to the disease’s most recognizable brain changes.
Michigan’s aging brains need more protection, poll shows
Lifestyle changes can reduce risk of Alzheimer’s disease and other forms of dementia but a poll shows many Michiganders over 50 don’t know about or do them.
Michigan’s aging brains need more protection, poll shows
Lifestyle changes can reduce risk of Alzheimer’s disease and other forms of dementia but a poll shows many Michiganders over 50 don’t know about or do them.
Important Steps You Can Take to Protect Brain Health as You Age
June is Alzheimer’s and Brain Awareness Month so Dr. Richard Isaacson joins TODAY to share important steps you can take to protect your brain as you age. Tips include putting a focus on learning, taking care of your teeth and more.
Researchers receive funding to launch USC’s first clinical study of psilocybin for mental health
Related News NIH investment totaling 30.7M will expand USC-led AI effort to decode Alzheimer’s disease April 2, 2026 USC study maps brain network changes linked to bipolar disorder severity and […]
This exercise ‘sweet spot’ is linked to greater longevity
A new study pinpoints how many minutes per week of strength training might help people avoid death from conditions including heart attacks and Alzheimer’s.
9 in 10 adults with Down syndrome develop Alzheimer’s. UNT Health research is exploring why
The goal is to better understand Alzheimer’s disease in people with Down syndrome, allowing scientists to develop treatment options.
We're at a turning point for heading off Alzheimer's disease
We're learning about risk factors we can do something about, just as we did decades ago with heart disease, writes Dr. Yogesh Shah.
ABC New York's Bill Ritter reveals Alzheimer's diagnosis on air, steps down from anchoring: ‘My life has taken a turn’
Bill Ritter announced he was stepping down from anchoring duties for ABC New York and revealed on air that he has been diagnosed with Alzheimer's: 'My life has taken a turn.'
Using AI for medical advice; pelvic floor exercises; the hidden dangers of burning incense; plus other stories with Vanderbilt Health sources
Colin Walsh, MD,Associate Professor of Biomedical Informatics, was on WTVF News Channel 5‘s “Morningline” show in an interview about whether or not it is safe to use AI for medical advice. Time magazine reporter Stacey Colino interviewed Elisabeth Sebesta, MD, Assistant Professor of Urology, for a story about pelvic floor exercises for issues including menopause, erectile dysfunction and urinary incontinence in men. “Each Breath,” published by the American Lung Association, quoted Brian Christman, MD, Adjunct Professor of Medicine, for a story about the hidden dangers of burning incense. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Healthline (low vaccination rates lead to more cases of measles, whooping cough and other preventable diseases); ABC News (U.S. measles cases surpass 2,000 for second year in a row); and CIDRAP News (high-dose flu shots cut rates of hospitalization in older adults). Sarah Rohde, MD, Associate Professor of Otolaryngology-Head and Neck Surgery, was quoted in a People magazine story on patient Makalii Andrade, a surfer from Kauai Island who suffered a serious neck injury in 2022 and recently underwent surgery at Vanderbilt Health to begin the final phase of his recovery. James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a piece in Nature about antibodies against a strain of Ebola. SFGATE reporter Gillian Mohney interviewed Xue Zhong, PhD, Research Assistant Professor, Division of Genetic Medicine and Clinical Pharmacology, for a story about a study of a blood test looking at Alzheimer’s disease biomarkers. Matthew Franklin Mart, MD, Assistant Professor of Medicine, was quoted in a Healio story about how inflammation and illness severity is linked to less cognitive resilience after a person has been an ICU patient. The “How We Really Feel” podcast host Sula Windgassen, PhD, interviewed Lindsey C. McKernan, PhD, MPH, Associate Professor of Psychiatry & Behavioral Sciences, Physical Medicine & Rehabilitation and Urology, for an episode focusing on pelvic and bladder health. The podcast is also available on YouTube and the podcast website. In addition, podcaster Monica Sanford interviewed cardiologist Mark Glazer, MD, for her podcast “The Monica Sanford Show”; the two-part interview is here and here.
Quit job at Fortune 500 company to care for mom, now can't pay bills
Kathy Mullen, 64, left her job at a Fortune 500 company to care for her mother with Alzheimer's, negatively impacting her health and finances.
New OMB rule could break science in the United States
The drug that saved your mother. The treatment your doctor recommended. The clinical trial that bought someone you love more time. None of it was inevitable. It required a system built to operate outside politics and sustained over decades, because science doesn’t operate on the timeline of a politician. That system is now under direct threat. The Office of Management and Budget (OMB) has proposed a new rule to regulate all federal grants, not just science, but housing, education, defense, NASA and everything in between, that would fundamentally change how research is conducted in the United States. There have been a lot of fires in the past 16 months, and if everything is an emergency, nothing is an emergency. But this is a very big deal. These rules would strip away the independence that has kept science from becoming a political tool. The good news is there’s still something we can all do. How the grant system was designed to work When I was a new faculty member, I was full of millions of ideas, so I sat down and wrote an NIH proposal. I worked on it for months and thought it was so good. Then I sent it to my mentor. It came back covered in comments. Places where my reasoning wasn’t as airtight as I’d thought, methods that could be stronger, gaps in my thinking that I had been too close to the work to see. It stung, as honest feedback always does, but peer review almost always makes the work better. In fact, it’s the backbone of how American science has functioned for generations. At NIH, submitted proposals go to a panel of scientists who have experience in the field. These are the people who can read research methods and spot their weaknesses, who understand when an experiment is designed well and when it isn’t. Applications are scored rigorously, and often only the top 3-20% of proposals receive funding. The people making funding decisions are required to justify them based on these reviews. To be clear: this is not a perfect system, and good science still goes unfunded more often than any of us would like due to limited resources. There is also criticism that peer review may undervalue bold ideas that are risky but could have high payoffs. But the peer review system is nonetheless a meaningful part of the grant selection process. While thoughtful and careful changes could improve the system, the changes being proposed by OMB will not make things better. The rule that could change everything Through this OMB proposal, the system that helps decide what gets funded is being dismantled. There are many troubling elements buried in this proposal, but three provisions stand out in particular. Each would be damaging alone. Together, they would change what kind of science gets done in America, and who it serves. 1. Political appointees would decide which science gets funded, and peer review would be explicitly sidelined or ignored. The guidelines your doctor follows, the standards that determine what’s in your air and water, the drugs that get approved for your family: all of it starts with a funding decision. Right now, that decision is made by scientists who can evaluate whether the work is actually sound and whether it could move the needle forward. Under this proposal, funding decisions could be made by political appointees. The careful, expertise-driven review process that shapes grant funding would be effectively sidelined. That means that a poorly designed study could get funded simply because someone in a political office liked the sound of it, while rigorous, important work doesn’t get funded because it no longer aligns with the administration’s priorities. In other words, critical work that benefits all of us could now be missed just because it has become politically inconvenient. 2. Grants could be canceled at any point, without warning, in the middle of ongoing work. Say your tax dollars have been paying for a cancer study for two years. The grant was awarded for five years, so the team is mid-experiment. There are three additional years’ worth of answers that could change how the disease is treated for hundreds of thousands of people. With this new rule, the federal government could cancel the remaining funding tomorrow, walk away from the commitment it made with your money, and have no legal obligation to finish what it started. This is a huge waste of money. There are rarely other sources of funding for this work, which means the team, the graduate students, postdocs, and research staff who have dedicated years of their careers to this project could lose their jobs. Patients who have contributed their time to studies may not see it turn into useful learnings for others. Every hour of work already completed could result in nothing useful. Science can take decades to get to tangible outcomes. It needs a stable funding system to flourish. 3. Researchers would have a harder time communicating their findings without pre-approval from the federal government. There is a saying from Sir Mark Walport: “Science isn’t finished until it’s communicated.” Science is no use to anyone if it is kept locked away in the labs that produced the data. The proposed rule could make communicating research findings harder in a number of ways: Make it harder for scientists to widely share their findings in scientific journals. Publication costs, including journal fees that allow for broad public access, could not be paid for by federal funds which is often how scientists pay these costs. Restrict researchers from engaging publicly about how their findings should inform policy or public health guidelines. This would restrict scientists from doing the work that transforms years of lab work into decisions that actually affect people’s lives. Make it harder for scientists to attend conferences. Conferences would now need to be approved by the federal agency at the time of grant award. This disadvantages conferences or publications that are not politically aligned. Conferences are a key way in which scientists learn about work happening in their field so they can collaborate and build on each other’s findings. What good is science with a muzzle? The long-term impact These changes could (and hopefully would) be reversed under the next administration. But by then, damage has been done. Once projects are halted or denied funding by political appointees, people leave their science careers for other paths or even leave the country to do their amazing science elsewhere. You cannot pause a scientific study the way you pause a subscription you decided isn’t useful anymore. You cannot freeze a research team that depends on salaries to feed their families, causing a scramble for replacement funding that, in most cases, simply does not exist. When the money stops, everything stops, and all the work in progress and its potential are lost. Despite all of the language about reducing waste, fraud, and abuse, this new proposed rule increases the administrative burden tremendously. Every researcher watching this unfold will make a rational decision: don’t start anything that will take a decade to finish. This includes not building a team around funding that could vanish, or asking the big questions that need patience and stability to answer. The most consequential science, the kind that produces the treatments and the breakthroughs that reach your doctor’s office twenty years from now, is exactly the science that would be abandoned first. This is still a proposal, so we can all do something Some worry this rule is already a done deal. But by law, OMB is required to open a public comment period. Those comments matter because they inform members of Congress, they can be used in litigation, and they create a public record. So here’s what you can do: Submit a public comment. The public comment period on this proposed change is open until July 13. Anyone can submit a comment, and OMB is required to respond to substantial ones. Each comment must be different to count as distinct; identical comments will be counted only once. Comment as an individual, not on behalf of your organization. Here’s a full resource to help you, with useful examples, but in general: Share a story about how science or federal funding has benefitted you or is involved in your work. Are you or someone you loved a cancer survivor? Do you know someone with Alzheimer’s? Have you received NIH/NSF or other federal funding? All of these can be stories you use to highlight why you care. Explain why you’re worried about these proposed changes. You can use the wording found here or in other resources to help you. Ask them to withdraw this proposed rule. Contact your elected representatives. Congress allocates money to federal agencies to spend, and it has oversight of how that process works. You can let your representatives know this proposed change concerns you and ask them to intervene. There are levers they can push that can help at this moment. Let others know why federal funding matters. This isn’t just about science, but ALL federal grants, including for education systems, defense projects, and more. The process, including the importance of federal funding, is invisible to many. We can all make it more visible by sharing how science benefits us and why we value it. You can also share this article, or any of the resources linked here, to help spread awareness! Bottom line We are quickly losing ground in scientific research in the U.S. More changes, like the proposed rule by OMB, would decimate our ability to conduct research here, leaving us all worse off: fewer treatments for pancreatic cancer, less research on pollution impacts, fewer answers for patients with rare disease, and more unaddressed health needs. The impact will be very real for all of us, regardless of where we stand politically. Using our voices for science is more important than ever. Love, LM Big thanks to Dr. Megan Ranney for reading this over and providing brilliant insights, as always. Dr. Liz Marnik, PhD, is Executive Director of The Evidence Collective at YLE and a science communicator and immunologist working at the intersection of public trust, science, and public health. You can find her on Substack, LinkedIn, Instagram and Threads. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
Popular joint supplement glucosamine linked to faster Alzheimer’s progression
A major study suggests glucosamine, a popular supplement for joint pain, could be linked to faster progression from mild cognitive impairment to Alzheimer’s disease. Researchers found a 25% higher likelihood of developing dementia among glucosamine users and uncovered biological clues that may explain why.
UToledo Health Now Offering FDA-Approved Infusion Therapy to Help Slow Early Alzheimer’s Progression
Kisunla targets amyloid plaques associated with Alzheimer's disease and is available to eligible patients with early symptomatic diagnoses.
Scientists found a new Alzheimer’s trigger and a drug that stops it
Researchers have identified a new Alzheimer’s target and created an experimental compound that blocks a damaging process inside brain cells. In mice, the treatment slowed nerve cell loss, reduced Alzheimer’s-related changes, and even appeared to promote healthier aging.
Alzheimer's Awareness Month: The Science Is Moving Fast
Explore the latest Alzheimer's research on the APOE e4 gene variant, new FDA-approved antiamyloid drugs, and how routine vaccines help reduce risk.
Beyond memory: FSU expert takes whole-body approach for Alzheimer's and Brain Awareness Month
June marks Alzheimer’s and Brain Awareness Month, an opportunity to foster public understanding for the most proactive brain health habits. A Florida
Beyond memory: FSU expert takes whole-body approach for Alzheimer's and Brain Awareness Month
June marks Alzheimer’s and Brain Awareness Month, an opportunity to foster public understanding for the most proactive brain health habits. A Florida
BEAM raises awareness of Alzheimer’s disease through community outreach, research
A UCLA club is partnering with local senior living homes and engaging in research to raise awareness about Alzheimer’s disease and dementia. Brain-Health Education and Advocacy Movement at UCLA works with the Mary S.
E-bike safety; lung cancer treatment and prevention; keeping CMA Festival attendees safe; plus other stories with Vanderbilt Health sources
WKRN News 2 interviewed Jeffrey Upperman, MD, FACS, Professor and Chair of the Department of Pediatric Surgery and Surgeon-in-Chief of Monroe Carell Jr. Children’s Hospital at Vanderbilt, about e-bike related injuries following the recent death of a Brentwood High student and a proposal to require safety training before students could ride a bike on a school campus in Williamson County. Fabien Maldonado, MD, MSc,Professor of Medicine and Thoracic Surgery, was on WTVF News Channel 5‘s live studio show, “Openline,” with host Ben Hall, to discuss lung cancer, treatment and prevention. WSMV’s “Today In Nashville” program hosted Vanderbilt LifeFlight paramedic/flight nurse practitioner Tony Smith to talk about safety for the CMA Festival. The New York Times reporter Carl Zimmer interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about the race to find vaccines and treatments as Ebola spreads. The Vanderbilt Health News release about the pilot clinical trial conducted by Vanderbilt Health and Cumberland Pharmaceuticals Inc., that confirms the safety of ifetroban and supports the further development of the drug to prevent cancer metastasis, was picked up by Reuters, Stock Titan,and others. Women We Admire has named Lee Ann Liska, President and Chief Operating Officer, to its list of top women leaders of Nashville for 2026. Radiology Business, Aunt Minnie, Bioengineer, and Imaging Technology News covered the study from Consuelo Wilkins, MD, MSCI, the Mildred Thornton Stahlman Professor in Rural Health and professor of Medicine in the Division of Geriatric Medicine, that found Black and Hispanic people, while known to be far more apt to have dementia, are significantly less apt than other racial and ethnic groups to show Alzheimer’s pathology on brain scans. STAT News interviewed Deva Sharma, MD, Transfusion Medicine & Hematology-Oncology, for a story about more patients requesting unvaccinated blood and what it means for the medical system at large. Yahoo! Health reporter Korin Miller interviewed Gitanjali Srivastava, MD, Director of Obesity Medicine, for a story about how semaglutide and tirzepatide compare. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: NBC News (new COVID vaccinations); Medscape (pneumonia and sepsis); and CNN (protection from contagious viruses). Shelbyville Times-Gazette is repurposing Jessica Pasley’s July 2025 Vanderbilt Health News story on tick-borne illnesses as a front-page story.
2026 Science of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) for Social Scientists Program - June 4, 2026
The Science of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) for Social Scientists Program is a unique two-day series of - 2026 Science of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) for Social Scientists Program June 4, 2026
Taking Action to Prevent Your Brain Health
Chartese Berry, Executive Director of the Alzheimer's Association joins Fox 5 DC.
A science powerhouse bets on genetic therapy to beat brain disorders
After spending two decades studying how the brain works, a huge team of scientists in Seattle is preparing to focus on treating brain diseases, including Alzheimer's and Parkinson's, using gene therapy.
Controversial Gene Therapy for Alzheimer’s Disease
Glial-to-neuron conversion therapy decreases inflammation and restores the brain-blood barrier in Alzheimer’s disease model macaques.
Scientists found the hidden switch fueling alzheimer’s brain inflammation
Scientists at Scripps Research have uncovered a molecular “switch” that appears to fuel the damaging brain inflammation seen in Alzheimer’s disease. They found that a protein called STING becomes chemically altered in a way that keeps the brain’s immune system stuck in overdrive, harming the connections between nerve cells.
Protein traffic jams may explain aging, memory loss, and Alzheimer’s
Scientists at Stanford may have uncovered a hidden reason our brains decline with age. Studying the ultra-short-lived turquoise killifish, researchers discovered that the cellular machinery responsible for building proteins begins to jam and malfunction over time. Tiny structures called ribosomes start colliding and stalling while reading genetic instructions, triggering a chain reaction that leads to faulty proteins and harmful clumps linked to diseases like Alzheimer’s.
Ozempic may be reshaping the brain, scientists say
The research has implications for addictive behaviors and diseases of aging such as Alzheimer’s.
Ozempic may be reshaping the brain, scientists say
The research has implications for addictive behaviors and diseases of aging such as Alzheimer’s.
Scientists create supercharged vitamin K that helps the brain heal itself
Scientists in Japan have created powerful new vitamin K-based compounds that may help the brain regenerate lost neurons — a breakthrough that could one day change how diseases like Alzheimer’s and Parkinson’s are treated. By combining vitamin K with components related to vitamin A, the researchers developed compounds that were about three times more effective at turning neural stem cells into neurons than natural vitamin K alone.
Banner Health report shows Arizona research driving national medical innovation
Milestones in Research details 1,300 clinical and translational research studies, FDA-approved heart device, landmark Alzheimer's prevention work Dr Wilber Su Wilber Su, MD, cardiologist for Banner Health, in the operating room. Phoenix, May 26, 2026 (GLOBE NEWSWIRE) -- Banner Health's $80.5 million research enterprise delivered breakthrough treatments to Arizona patients in 2025 while advancing wide-ranging therapies toward FDA approval, according to the organization's annual Milestones in Rese
USC scientists discover a hidden Alzheimer’s trigger and a possible way to shut it down
USC researchers have identified potential new drug compounds that may reduce the brain inflammation linked to Alzheimer’s disease, especially in people with the high-risk APOE4 gene. The compounds target cPLA2, an enzyme that seems to fuel harmful inflammation while also being important for normal brain activity.
Experimental Alzheimer’s drug could reduce alcohol withdrawal damage, researchers say
Researchers say an experimental Alzheimer's drug may calm brain inflammation linked to alcohol withdrawal, potentially reducing relapse and neural damage.
Novartis says Avidity's science could apply beyond muscular dystrophies
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences buyout.
Scientists discover hidden weakness shared by hundreds of cancer mutations
Scientists have unveiled a powerful new tool called PerturbFate that could change how researchers tackle diseases driven by huge numbers of genetic mutations, including cancer and Alzheimer’s. Instead of trying to target every faulty gene individually, the system tracks how different mutations reshape cells over time and identifies the hidden “control hubs” where those pathways converge.
Scientists found a hidden Alzheimer’s trigger and shut it down
A newly identified enzyme called IDOL could become a major new target in the fight against Alzheimer’s disease. Researchers found that removing it from neurons sharply reduced amyloid plaques and improved key brain processes linked to resilience and communication between cells. The discovery may lead to future treatments that go beyond slowing Alzheimer’s — potentially helping protect the brain from further decline.
Scientists discover why Alzheimer’s risk hits women so much harder
Women may be especially sensitive to the effects of common dementia risk factors, according to a new UC San Diego study of over 17,000 adults. Researchers say tailoring prevention strategies specifically for women could be key to reducing Alzheimer’s risk.
'A hidden blood pump': How chewing more boosts your brain
While it's widely known that chewing more improves digestion, research suggests it can also boost our brains and even help fend off Alzheimer's.
Scientists reverse Alzheimer’s in mice with breakthrough nanotechnology
A new nanotechnology treatment reversed Alzheimer’s symptoms in mice by restoring the brain’s natural cleanup system. The specially engineered nanoparticles helped clear toxic amyloid proteins from the brain and repair the blood-brain barrier, which normally protects and regulates the brain’s environment. In one striking experiment, elderly mice treated with the therapy later behaved like healthy younger mice.
Scientists reversed memory loss by recharging the brain’s tiny engines
Researchers have shown for the first time that malfunctioning mitochondria — the cell’s energy generators — may directly cause cognitive decline in neurodegenerative diseases. By creating a new tool that temporarily boosts mitochondrial activity in the brain, scientists restored memory performance in mouse models of dementia. The discovery hints that energy failure inside neurons could happen before brain cells die, potentially offering a new target for future Alzheimer’s treatments.
Better brain health linked to resilience against early Alzheimer's in adults 65 to 80
A healthy brain may help protect thinking and memory skills from the early effects of Alzheimer's disease, a new study has found. Dementia is currently the leading cause of death in Australia and Alzheimer's ...
Challenging your mind can help maintain brain health. Here are steps the Alzheimer's Association recommends.
How does diet impact brain health? Alzheimer's Association shares nutrition tips with cognitive function in mind.
This daily habit could lower dementia risk by 35%, scientists say
A huge long-term study found that drinking two to three cups of coffee a day was linked to a much lower risk of dementia, especially before age 75. Researchers say caffeine may help keep brain cells active while reducing inflammation and harmful plaque buildup associated with Alzheimer’s disease. But more coffee wasn’t better — the protective effect appeared to level off after moderate intake.
How can movement boost your brain health? Alzheimer's Association unveils new daily challenge
Medicare’s miss on Alzheimer’s drug spending
Far fewer seniors than expected are taking costly Alzheimer's drugs.
New infusion therapies can put cognitive decline on pause. What Louisianans should know about brain health.
Learn about the five pillars of healthy brain aging and the latest research on cognitive decline, Alzheimer's disease, and strategies for maintaining brain health through lifestyle changes.
Women’s Health Watch: Maria Shriver explains the gender disparity in Alzheimer’s research
New WAM Grants Support Research on Gut-Brain Interactions, Menopause and Sarcopenia
The Women’s Alzheimer’s Movement (WAM) at Cleveland Clinic has awarded grants for promising research in sex-based differences in the disease.